Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

NCT06295731 is registered in ClinicalTrials.gov with Inhibrx Biosciences, Inc as lead sponsor.

NCT NCT06295731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06295731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)
Lead sponsor
Inhibrx Biosciences, Inc
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 14, 2024
Completion date
May 31, 2029
Enrollment
410 (estimated)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc)